HEP Drug Interactions

Currently 170 million people worldwide are infected with the hepatitis C virus (HCV) and >300 million with hepatitis B (HBV). Although interferon-free combination direct acting antivirals (DAAs) regimens have improved tolerability and efficacy for HCV-infected patients, drug-drug interactions (DDIs) have the potential to cause harm due to liver dysfunction, multiple comorbidities and comedications. This web site was established in 2010 by members of the Department of Pharmacology at the University of Liverpool to offer a resource for healthcare providers, researchers and patients to be able to understand and manage drug-drug interactions.目前全球共有1.7亿人感染丙型肝炎病毒（hepatitis C virus, HCV），超3亿人感染乙型肝炎病毒（hepatitis B, HBV）。尽管无干扰素联合直接抗病毒药物（direct acting antivirals, DAAs）方案已提升了丙型肝炎病毒感染者的用药耐受性与治疗疗效，但由于肝功能异常、多种合并症及合并用药，药物相互作用（drug-drug interactions, DDIs）仍存在引发机体损害的风险。该网站由利物浦大学药理学系团队于2010年创建，旨在为医疗从业者、科研人员与患者提供可用于了解和管理药物相互作用的资源支持。

搜集汇总

背景与挑战

背景概述

HEP Drug Interactions是一个专注于肝炎病毒（包括HCV和HBV）药物相互作用的在线资源平台，由利物浦大学药理学部门建立。它提供免费的药物相互作用检查工具、教育视频和处方资源，以帮助医疗保健提供者、研究者和患者理解和处理药物相互作用问题。